I-Mab(US:IMAB)2026-03-09 14:02NovaBridge Biosciences Update Summary Company Overview - Company: NovaBridge Biosciences (NasdaqGM:IMAB) - Focus: Global biotech platform with a hub-and-spoke business model, primarily in ophthalmology and oncology sectors - Lead Assets: - VIS-101: A molecule targeting VEGF-A and ANG-2, designed for retinal vascular diseases - Givastomig: A bispecific antibody for gastric cancer, targeting Claudin 18.2 and 4-1BB - Financial Position: As of the last SEC filing, the company has $228 million in cash, providing operational runway through 2028 [5][6] Industry Context - Market Need: Over 57 million people globally are affected by retinal vascular diseases, including wet AMD, diabetic macular edema, and retinal vein occlusion, indicating a significant unmet need for effective therapies [16][17] - Competitive Landscape: Current treatments like Lucentis and Eylea have shorter treatment intervals, while VIS-101 aims for longer intervals (Q8 to Q24 weeks) [18][19] Clinical Development - VIS-101 Phase IIa Trial: - Design: Multicenter, open-label, randomized study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with neovascular AMD [25][26] - Patient Population: 38 patients randomized in a 2-to-1 ratio to receive either 6 mg or 3 mg of VIS-101 [26] - Results: - Rapid and robust BCVA gain observed, with approximately 70% of treatment-naive patients being treatment-free at 4 months and about 40% at 6 months [31][32] - Central subfield thickness (CST) decreased by over 100 microns after the first injection [31] - Safety profile: Well-tolerated with no dose-limiting toxicities reported [34] Key Findings - Durability: VIS-101 demonstrated a potential best-in-class durability with treatment-free intervals extending up to 24 weeks [40] - Comparison with Competitors: VIS-101 shows double the anti-VEGF inhibition and 17 times the anti-ANG-2 inhibition compared to faricimab [35] - Management Team: Led by experienced professionals, including Dr. Emmett Cunningham, who has a strong background in ophthalmology and drug development [11][12] Future Plans - Next Steps: - Initiation of Phase IIb study in China in the second half of 2026 - Global Phase III program expected to begin in 2027 [40][41] - Partnership Strategy: Open to discussions for partnerships but currently does not require one for global development [70] Additional Insights - Clinical Trial Design: The trial's retreatment criteria were designed to prioritize patient safety, requiring either a decrease in vision or an increase in anatomical parameters for retreatment [53] - Regulatory Considerations: Future trials will likely focus on treatment-naive patients, as regulatory agencies prefer this population for clearer efficacy assessments [79] This summary encapsulates the key points from the NovaBridge Biosciences update, highlighting the company's strategic focus, clinical advancements, and future directions in the biotech landscape.